You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Proteolytic Imaging of Remodeling Myocardium

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTIONprovided by applicantProteolytic Imaging of Remodeling Myocardium Abstract Heart attacksi emyocardial infarction or MIoccur in more thanmillion patients annuallyAdvances in interventional and pharmacological therapies have dramatically improved survival following the initial MIand patients are often surviving acute MI with more extensive myocardial injuryConsequentlythe number of patien ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples

    SBC: CIRCA BIOSCIENCE LLC            Topic: 102

    Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Stroke Treatment by Chemically-Induced Hypothermia

    SBC: HALIMED PHARMACEUTICALS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the United States. In spite of intensive investigations, clinical therapies for treating acute stroke patients remain limited and unsatisfactory. There are consistent animal and human data that mild to moderate hypothermia (reducing body temperature to 32-34oC) is generally safe and improves outcome after brain ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Using a novel model of antidepressant efficacy to discover new compounds and personalized treatments.

    SBC: PAX NEUROSCIENCE, INC.            Topic: 102

    The World Health Organization estimates that bymajor depressive disorderMDDwill be the most common cause of disabilityworldwideAlthough approximatelyinAmericans will suffer from MDD during their lifetimemany patients with MDD go undiagnosed in primary care settingsandare incorrectly diagnosed with MDDGiven the substantial medicaleconomic and social costs involved with MDDthere is tremendous need f ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Delivery of chemically modified PNA oligomers

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARYRNA is a validated target for drug design, both as therapeutic and as a target. Targeting specific RNA, such as rRNA which are involved in proliferation and survival of bacteria is a promising approach. We are developing fast and low cost methods to screen sequence-specific small molecules for novel anti-ribosomal activities. We will construct sequence-specific chemically modified r ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Continuous Monitoring of COVID-19 Symptomatology for Elderly Patients in Long Term Care Facilities Using Advanced, Soft, and Flexible Sensors Mounted on the Suprasternal Notch

    SBC: Sonica LLC            Topic: NIA

    PROJECT SUMMARY: COVID-19 is significantly more lethal in the elderly1 with the greatest risk in those cared for in long-term care facilities (LTCs) where mortality rates range from 19% to 72% worldwide. Monitoring COVID-19 infections in LTCs remains a particular challenging. The existing and a continued expected shortage of sufficient molecular COVID-19 testing coupled to false negative rates as ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Aminomethyl benzamides as novel anti Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. HLS13-13 Albumin nanoparticle based technology to treat ARDS

    SBC: CELL BIOLOGICS INC            Topic: NHLBI

    DESCRIPTION provided by applicant Severe infections various types of trauma and other etiologic factors can cause ALI that rapidly morphs into ARDS The incidence of ALI ARDS is around in adults in US alone Despite medical advances and better management through ventilation intervention the mortality is still unacceptably high at This problem is likely to escalate given the a ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: NCI

    Project Summary/Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Poor survival rates are largely due to the late stage at which PDAC is diagnosed and a lack of effective targeted therapies. While the field of immunotherapy has significantly increased overall survival in some malignancies, they have not translated to PDAC. The long-term goal of this research ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government